The FDA on December 20, 2017 granted regular approval to PERJETA® for use in combination with Trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. PERJETA® is a product of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
